首页 | 本学科首页   官方微博 | 高级检索  
     

术前调强放疗联合替吉奥化疗对局部晚期直肠癌患者的疗效回顾分析
引用本文:马 欢,焦英华,李曙光,张贤雨,魏玉磊,田桂英,卢秀荣,原 娜. 术前调强放疗联合替吉奥化疗对局部晚期直肠癌患者的疗效回顾分析[J]. 现代生物医学进展, 2020, 0(10): 1979-1983
作者姓名:马 欢  焦英华  李曙光  张贤雨  魏玉磊  田桂英  卢秀荣  原 娜
作者单位:河北北方学院附属第一医院放疗科 河北 张家口075000;河北北方学院附属第一医院胃肠肿瘤外科 河北 张家口075000;河北北方学院附属第一医院胸外科 河北 张家口075000
基金项目:河北省卫生厅科研基金项目(20190878);张家口市科技攻关计划项目(1321064D)
摘    要:目的:探讨术前调强放疗联合替吉奥化疗对局部晚期直肠癌患者的疗效。方法:回顾性分析2012年12月至2014年12月我院收治的局部晚期直肠癌患者90例进行研究,根据治疗方法分为三组:A组(n=30)给予术前调强放疗联合替吉奥化疗治疗,B组(n=30)仅给予术前调强放疗治疗,C组(n=30)给予替吉奥化疗治疗。比较三组患者的总有效率,血清TPS、CYFRA21-1水平变化情况,1年、2年、3年复发、转移、生存率,保肛率及不良反应发生情况。结果:A组总有效率86.68%显著高于对照B组的46.67%和C组的50.00%,差异显著(P0.05);治疗前,三组TPS、CYFRA21-1水平无显著差异(P0.05);治疗后,三组TPS、CYFRA21-1水平均显著下降,且A组低于B组和C组(P0.05);三组患者1年、2年复发、转移情况无显著差异;A组3年复发、转移情况均显著低于B组和C组(P0.05);三组患者1年、2年生存率无显著差异;A组3年生存率均显著高于B组和C组(P0.05);三组患者发生恶心呕吐、白细胞减少等并发症发生情况无显著差异;A组保肛率均显著高于B组和C组(P0.05)。结论:采用术前调强放疗联合替吉奥化疗治疗局部晚期直肠癌疗效好于术前放疗。

关 键 词:术前调强放疗;替吉奥;局部晚期直肠癌;组织多肽特异性抗原;细胞角蛋白19片段抗原21-1
收稿时间:2020-01-07
修稿时间:2020-01-31

Retrospective Analysis of the Effect of Preoperative Intensity-modulated Radiotherapy Combined with Tiogio Chemotherapy on Patients with Locally Advanced Rectal Cancer
MA Huan,JIAO Ying-hu,LI Shu-guang,ZHANG Xian-yu,WEI Yu-lei,TIAN Gui-ying,LU Xiu-rong,YUAN Na. Retrospective Analysis of the Effect of Preoperative Intensity-modulated Radiotherapy Combined with Tiogio Chemotherapy on Patients with Locally Advanced Rectal Cancer[J]. Progress in Modern Biomedicine, 2020, 0(10): 1979-1983
Authors:MA Huan  JIAO Ying-hu  LI Shu-guang  ZHANG Xian-yu  WEI Yu-lei  TIAN Gui-ying  LU Xiu-rong  YUAN Na
Affiliation:Department of Radiotherapy, First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, 075000, China;Department of Gastrointestinal Tumor Surgery, First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, 075000, China;Department of Thoracic Surgery, First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, 075000, China
Abstract:ABSTRACT Objective: To studya retrospective analysis of the efficacy of preoperative imrt combined with tiggio chemotherapy in patients with advanced rectal cancer. Methods: A retrospective analysis of 90 patients with advanced rectal cancer admitted to our hospital from December 2012 to December 2014 was conducted. According to the treatment methods, they were divided into three groups. Group A (n=30) was given preoperative intensity modulated radiation therapy combined with teggio chemotherapy. Group B (n=30) was treated with preoperative intensity modulated radiation therapy, while group C(n=30) was given chemotherapy with teggio. The total effective rate, serum TPS, CYFRA21-1 level, recurrence, metastasis, survival rate, anus preserving rate and adverse reactions were compared among the three groups. Results: The total effective rate of group A was 86.68%, significantly higher than 46.67% of group B and 50.00% of group C, with significant difference (P<0.05); before treatment, there was no significant difference in TPS and CYFRA21-1 levels among the three groups (P>0.05); After treatment, TPS and CYFRA21-1 levels of the three groups were significantly decreased, and group A was lower than group B and group C(P<0.05); there was no significant difference in recurrence and metastasis of the three groups in one and two years; there was no significant difference in recurrence and metastasis of group A in three years (P<0.05). The three-year survival rate of group A was significantly higher than that of group B and group C (P<0.05); the three-year survival rate of group A was significantly higher than that of group B and group C (P<0.05); nausea and vomiting, leukopenia occurred in all three groups, and there was no significant difference in the incidence of complications; the anal preservation rate of group A was significantly higher than that of group B and group C (P<0.05). Conclusion: The efficacy of preoperative intensity modulation combined with tiggol in the treatment of rectal cancer was better than that of preoperative radiotherapy.
Keywords:Preoperative intensity modulated radiotherapy   On behalf of gonow   Advanced rectal cancer   Tissue polypeptide specific antigen   Cytokeratin 19 fragment antigen 21-1
本文献已被 CNKI 等数据库收录!
点击此处可从《现代生物医学进展》浏览原始摘要信息
点击此处可从《现代生物医学进展》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号